Autophagy, a conserved catabolic process, plays an immensely significant role in a variety
of diseases. However, whether it imparts a protective function in diseases remains …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …

Importance Exenatide, a glucagon-like peptide 1 agonist used in type 2 diabetes, was
recently found to have beneficial effects on motor function in a randomized, placebo …

Dementia is a permanent illness characterized by mental instability, memory loss, and
cognitive decline. Many studies have demonstrated an association between diabetes and …

Diabetes mellitus (DM) is a gradually rising metabolic disease which is currently affecting
millions of people worldwide. Diabetes is associated with various complications like …

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD) and both
have the same pathogenesis (eg, insulin resistance), drugs used to treat T2DM have been …

ABSTRACT Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however,
its function in the brain is not well studied. In this systematic review, we aimed to analyze the …

Abstract The glucagon-like peptide-1 (GLP-1) was shown to have neuroprotective effects in
Alzheimer's disease (AD). However, the underlying mechanism remains elusive. Astrocytic …

Most neurodegenerative diseases show a disruption of autophagic function and display
abnormal accumulation of toxic protein aggregates that promotes cellular stress and death …